Research article
Haplotype analysis of TP53 polymorphisms, Arg72Pro and Ins16, in BRCA1 and BRCA2 mutation carriers of French Canadian descent
-
* Corresponding author: Patricia N Tonin patricia.tonin@mcgill.ca
1 Department of Human Genetics, McGill University, Montreal, Canada
2 The Research Institute of the McGill University Health Centre, Montreal, Canada
3 Service de Médecine Génique, Centre Hospitalier de l'Université de Montréal (CHUM), Montreal, Canada
4 Département de médecine, Université de Montréal, Montreal, Canada
5 Epidemiology Research Unit, Research Centre, CHUM – Hôtel-Dieu, Montreal, Canada
6 Centre de Recherche du Centre Hospitalier de l'Université de Montréal/Institut du Cancer de Montréal, Hôpital Notre-Dame, Montreal, Canada
7 Département d'obstétrique gynécologie, Division de gynécologie oncologique, Université de Montréal, Montreal
8 Department of Medicine, McGill University, Montreal, Canada
BMC Cancer 2008, 8:96 doi:10.1186/1471-2407-8-96
Published: 10 April 2008Abstract
Background
The TP53 polymorphisms Arg72Pro (Ex4+199 G>C) and Ins16 (IVS3+24 ins16) have been proposed to modify risk of breast cancer associated with germline BRCA1 and BRCA2 mutations. Allele frequencies of these polymorphisms were investigated to determine if they modify risk in BRCA mutation carriers in breast cancer cases drawn from French Canadian cancer families, a population shown to exhibit strong founder effects.
Methods
The frequencies of the TP53 alleles, genotypes and haplotypes of 157 index breast cancer cases comprised of 42 BRCA1 mutation carriers, 57 BRCA2 mutation carriers, and 58 BRCA mutation-negative cases, where each case was drawn from independently ascertained families were compared. The effect of TP53 variants on the age of diagnosis was also investigated for these groups. The TP53 polymorphisms were also investigated in 112 women of French Canadian descent with no personal history of cancer.
Results
The BRCA mutation-positive groups had the highest frequency of homozygous carriers of the 72Pro allele compared with mutation-negative group. The TP53 polymorphisms exhibited linkage disequilibrium (p < 0.001), where the 72Arg and Ins16minus alleles occurred in strong disequilibrium. The highest frequency of carriers of Ins16minus-72Arg haplotype occurred in the BRCA mutation-negative groups. The BRCA1 mutation carriers homozygous for the 72Pro allele had the youngest ages of diagnosis of breast cancer. However none of these observations were statistically significant. In contrast, the BRCA2 mutation carriers homozygous for the 72Pro allele had a significantly older age of diagnosis of breast cancer (p = 0.018). Moreover, in this group, the mean age of diagnosis of breast cancer in carriers of the Ins16minus-72Arg haplotype was significantly younger than that of the individuals who did not this carry this haplotype (p = 0.009).
Conclusion
We observed no significant association of breast cancer risk with TP53 genetic variants based on BRCA1/2 mutation carrier status. Although the small sample size did not permit analysis of all possible haplotypes, we observed that BRCA2 mutation carriers harboring the Ins16minus-72Arg haplotype had a significantly younger mean age of diagnosis of breast cancer. These observations suggest that investigations in a larger French Canadian sample are warranted to further elucidate the effects of TP53 variants on age of diagnosis of breast cancer among BRCA1 and BRCA2 mutation carriers.